Literature DB >> 32008067

Brain-derived neurotrophic factor-TrkB signaling and the mechanism of antidepressant activity by ketamine in mood disorders.

Kenji Hashimoto1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32008067     DOI： 10.1007/s00406-020-01095-1

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN： 0940-1334            Impact factor:   5.270


× No keyword cloud information.
  12 in total

1.  Brain-derived neurotrophic factor (BDNF) and its precursor proBDNF as diagnostic biomarkers for major depressive disorder and bipolar disorder.

Authors:  Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-11-02       Impact factor: 5.270

2.  Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model.

Authors:  Lijia Chang; Kai Zhang; Yaoyu Pu; Youge Qu; Si-Ming Wang; Zhongwei Xiong; Yukihiko Shirayama; Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-03-29       Impact factor: 5.270

3.  Longitudinal multi-level biomarker analysis of BDNF in major depression and bipolar disorder.

Authors:  Katrin Schröter; Murielle Brum; Nathalie Brunkhorst-Kanaan; Franziska Tole; Christiane Ziegler; Katharina Domschke; Andreas Reif; Sarah Kittel-Schneider
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-03-30       Impact factor: 5.270

4.  Higher BDNF plasma levels are associated with a normalization of memory dysfunctions during an antidepressant treatment.

Authors:  Jan Engelmann; Stefanie Wagner; Daniel Wollschläger; Sabine Kaaden; Konrad F Schlicht; Nadine Dreimüller; Dieter F Braus; Marianne B Müller; Oliver Tüscher; Helge Frieling; André Tadić; Klaus Lieb
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-03-30       Impact factor: 5.270

Review 5.  Esketamine: a glimmer of hope in treatment-resistant depression.

Authors:  Upinder Kaur; Bhairav Kumar Pathak; Amit Singh; Sankha Shubhra Chakrabarti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-11-19       Impact factor: 5.270

6.  Default mode network connectivity change corresponds to ketamine's delayed glutamatergic effects.

Authors:  Meng Li; Marie Woelfer; Lejla Colic; Adam Safron; Catie Chang; Hans-Jochen Heinze; Oliver Speck; Helen S Mayberg; Bharat B Biswal; Giacomo Salvadore; Anna Fejtova; Martin Walter
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-10-23       Impact factor: 5.270

7.  Brain-derived neurotrophic factor-TrkB signaling in the medial prefrontal cortex plays a role in the anhedonia-like phenotype after spared nerve injury.

Authors:  Xi Fang; Chun Yang; Shan Li; Gaofeng Zhan; Jie Zhang; Niannian Huang; Xiangxi Du; Hui Xu; Kenji Hashimoto; Ailin Luo
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-06-07       Impact factor: 5.270

Review 8.  Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites.

Authors:  Chun Yang; Jianjun Yang; Ailin Luo; Kenji Hashimoto
Journal:  Transl Psychiatry       Date:  2019-11-07       Impact factor: 6.222

9.  Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.

Authors:  Allison C Nugent; Elizabeth D Ballard; Todd D Gould; Lawrence T Park; Ruin Moaddel; Nancy E Brutsche; Carlos A Zarate
Journal:  Mol Psychiatry       Date:  2018-02-27       Impact factor: 15.992

10.  Key role of gut microbiota in anhedonia-like phenotype in rodents with neuropathic pain.

Authors:  Chun Yang; Xi Fang; Gaofeng Zhan; Niannian Huang; Shan Li; Jiangjiang Bi; Riyue Jiang; Ling Yang; Liying Miao; Bin Zhu; Ailin Luo; Kenji Hashimoto
Journal:  Transl Psychiatry       Date:  2019-01-31       Impact factor: 6.222
View more
  4 in total

Review 1.  Dysfunctional Heteroreceptor Complexes as Novel Targets for the Treatment of Major Depressive and Anxiety Disorders.

Authors:  Miguel Pérez de la Mora; Dasiel O Borroto-Escuela; Minerva Crespo-Ramírez; José Del Carmen Rejón-Orantes; Daniel Alejandro Palacios-Lagunas; Magda K Martínez-Mata; Daniela Sánchez-Luna; Emiliano Tesoro-Cruz; Kjell Fuxe
Journal:  Cells       Date:  2022-06-02       Impact factor: 7.666

2.  Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia.

Authors:  Mitchell J Bartlett; Andrew J Flores; Tony Ye; Saskia I Smidt; Hannah K Dollish; Jennifer A Stancati; Drew C Farrell; Kate L Parent; Kristian P Doyle; David G Besselsen; Michael L Heien; Stephen L Cowen; Kathy Steece-Collier; Scott J Sherman; Torsten Falk
Journal:  Exp Neurol       Date:  2020-07-25       Impact factor: 5.330

3.  Repeated intermittent administration of (R)-ketamine during juvenile and adolescent stages prevents schizophrenia-relevant phenotypes in adult offspring after maternal immune activation: a role of TrkB signaling.

Authors:  Yunfei Tan; Yuko Fujita; Yaoyu Pu; Lijia Chang; Youge Qu; Xinming Wang; Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-01-03       Impact factor: 5.760

4.  Decreased DNA methylation at promoters and gene-specific neuronal hypermethylation in the prefrontal cortex of patients with bipolar disorder.

Authors:  Miki Bundo; Junko Ueda; Yutaka Nakachi; Kiyoto Kasai; Tadafumi Kato; Kazuya Iwamoto
Journal:  Mol Psychiatry       Date:  2021-04-20       Impact factor: 15.992
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.